7-Nitroindazole

Identification

Name
7-Nitroindazole
Accession Number
DB02207  (EXPT00314)
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
UNII
UX0N37CMVH
CAS number
2942-42-9
Weight
Average: 163.1335
Monoisotopic: 163.038176419
Chemical Formula
C7H5N3O2
InChI Key
PQCAUHUKTBHUSA-UHFFFAOYSA-N
InChI
InChI=1S/C7H5N3O2/c11-10(12)6-3-1-2-5-4-8-9-7(5)6/h1-4H,(H,8,9)
IUPAC Name
7-nitro-2H-indazole
SMILES
O=N(=O)C1=CC=CC2=CNN=C12

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UNitric oxide synthase, endothelialNot AvailableHuman
UNitric oxide synthase, inducibleNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with 7-Nitroindazole.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with 7-Nitroindazole.Approved
AdipiplonThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with 7-Nitroindazole.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with 7-Nitroindazole.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with 7-Nitroindazole.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with 7-Nitroindazole.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Amperozide.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with 7-Nitroindazole.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with 7-Nitroindazole.Approved
AzaperoneThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Azaperone.Investigational, Vet Approved
Azelastine7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with 7-Nitroindazole.Illicit
BenperidolThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with 7-Nitroindazole.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Benzyl alcohol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with 7-Nitroindazole.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with 7-Nitroindazole.Approved, Investigational
Buprenorphine7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with 7-Nitroindazole.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with 7-Nitroindazole.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with 7-Nitroindazole.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with 7-Nitroindazole.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with 7-Nitroindazole.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with 7-Nitroindazole.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with 7-Nitroindazole.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with 7-Nitroindazole.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with 7-Nitroindazole.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with 7-Nitroindazole.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with 7-Nitroindazole.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with 7-Nitroindazole.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with 7-Nitroindazole.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with 7-Nitroindazole.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with 7-Nitroindazole.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with 7-Nitroindazole.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with 7-Nitroindazole.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with 7-Nitroindazole.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with 7-Nitroindazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with 7-Nitroindazole.Approved
DesipramineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with 7-Nitroindazole.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with 7-Nitroindazole.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with 7-Nitroindazole.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with 7-Nitroindazole.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with 7-Nitroindazole.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with 7-Nitroindazole.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with 7-Nitroindazole.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with 7-Nitroindazole.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with 7-Nitroindazole.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with 7-Nitroindazole.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with 7-Nitroindazole.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with 7-Nitroindazole.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with 7-Nitroindazole.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with 7-Nitroindazole.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with 7-Nitroindazole.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with 7-Nitroindazole.Approved
Ethanol7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with 7-Nitroindazole.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with 7-Nitroindazole.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with 7-Nitroindazole.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with 7-Nitroindazole.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with 7-Nitroindazole.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with 7-Nitroindazole.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with 7-Nitroindazole.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with 7-Nitroindazole.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with 7-Nitroindazole.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with 7-Nitroindazole.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with 7-Nitroindazole.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with 7-Nitroindazole.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with 7-Nitroindazole.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Fospropofol.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with 7-Nitroindazole.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with 7-Nitroindazole.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with 7-Nitroindazole.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with 7-Nitroindazole.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with 7-Nitroindazole.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with 7-Nitroindazole.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with 7-Nitroindazole.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with 7-Nitroindazole.Approved
Hydrocodone7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with 7-Nitroindazole.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.Approved
IloperidoneThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Indiplon.Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with 7-Nitroindazole.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with 7-Nitroindazole.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with 7-Nitroindazole.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Ketobemidone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with 7-Nitroindazole.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with 7-Nitroindazole.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with 7-Nitroindazole.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with 7-Nitroindazole.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with 7-Nitroindazole.Approved
LofentanilThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with 7-Nitroindazole.Approved
LormetazepamThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with 7-Nitroindazole.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with 7-Nitroindazole.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Medetomidine.Vet Approved
MefloquineThe therapeutic efficacy of 7-Nitroindazole can be decreased when used in combination with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with 7-Nitroindazole.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with 7-Nitroindazole.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with 7-Nitroindazole.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with 7-Nitroindazole.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with 7-Nitroindazole.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with 7-Nitroindazole.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with 7-Nitroindazole.Approved
Methotrimeprazine7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with 7-Nitroindazole.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with 7-Nitroindazole.Approved
Metyrosine7-Nitroindazole may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of 7-Nitroindazole can be decreased when used in combination with Mianserin.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with 7-Nitroindazole.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.Approved, Investigational
Mirtazapine7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with 7-Nitroindazole.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with 7-Nitroindazole.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with 7-Nitroindazole.Approved
NefazodoneThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with 7-Nitroindazole.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with 7-Nitroindazole.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with 7-Nitroindazole.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with 7-Nitroindazole.Approved
OpiumThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Opium.Approved, Illicit
OrlistatThe serum concentration of 7-Nitroindazole can be decreased when it is combined with Orlistat.Approved, Investigational
Orphenadrine7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with 7-Nitroindazole.Approved
OxethazaineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with 7-Nitroindazole.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with 7-Nitroindazole.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with 7-Nitroindazole.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with 7-Nitroindazole.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with 7-Nitroindazole.Approved
Paraldehyde7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with 7-Nitroindazole.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with 7-Nitroindazole.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.Approved
PerazineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with 7-Nitroindazole.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with 7-Nitroindazole.Approved
PhenazocineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with 7-Nitroindazole.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Phenoxyethanol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with 7-Nitroindazole.Approved
PipamperoneThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Pomalidomide.Approved
Pramipexole7-Nitroindazole may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with 7-Nitroindazole.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with 7-Nitroindazole.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with 7-Nitroindazole.Approved
PrimidoneThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with 7-Nitroindazole.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with 7-Nitroindazole.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with 7-Nitroindazole.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with 7-Nitroindazole.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with 7-Nitroindazole.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with 7-Nitroindazole.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with 7-Nitroindazole.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with 7-Nitroindazole.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with 7-Nitroindazole.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with 7-Nitroindazole.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with 7-Nitroindazole.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Romifidine.Vet Approved
Ropinirole7-Nitroindazole may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with 7-Nitroindazole.Approved
Rotigotine7-Nitroindazole may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with 7-Nitroindazole.Approved
ScopolamineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with 7-Nitroindazole.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with 7-Nitroindazole.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.Approved
StiripentolThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with 7-Nitroindazole.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with 7-Nitroindazole.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Sultopride.Experimental
Suvorexant7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.Approved
TasimelteonThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with 7-Nitroindazole.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tetrodotoxin.Investigational
Thalidomide7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with 7-Nitroindazole.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with 7-Nitroindazole.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with 7-Nitroindazole.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with 7-Nitroindazole.Approved
TiagabineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with 7-Nitroindazole.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with 7-Nitroindazole.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with 7-Nitroindazole.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with 7-Nitroindazole.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with 7-Nitroindazole.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with 7-Nitroindazole.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with 7-Nitroindazole.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of 7-Nitroindazole can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with 7-Nitroindazole.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with 7-Nitroindazole.Approved
ZolazepamThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Zolazepam.Vet Approved
Zolpidem7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with 7-Nitroindazole.Approved
ZotepineThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with 7-Nitroindazole.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
1893
PubChem Substance
46504896
ChemSpider
1821
BindingDB
50209245
ChEMBL
CHEMBL247378
HET
7NI
PDB Entries
1foj / 1m8e / 1m9k

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility4.23 mg/mLALOGPS
logP1.76ALOGPS
logP1.59ChemAxon
logS-1.6ALOGPS
pKa (Strongest Acidic)10.22ChemAxon
pKa (Strongest Basic)-0.39ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area74.5 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity43.15 m3·mol-1ChemAxon
Polarizability14.49 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9911
Blood Brain Barrier+0.9745
Caco-2 permeable+0.5178
P-glycoprotein substrateNon-substrate0.8679
P-glycoprotein inhibitor INon-inhibitor0.9266
P-glycoprotein inhibitor IINon-inhibitor0.8616
Renal organic cation transporterNon-inhibitor0.8509
CYP450 2C9 substrateNon-substrate0.8587
CYP450 2D6 substrateNon-substrate0.8483
CYP450 3A4 substrateNon-substrate0.5888
CYP450 1A2 substrateInhibitor0.9418
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.6791
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5437
Ames testAMES toxic0.9122
CarcinogenicityNon-carcinogens0.7306
BiodegradationNot ready biodegradable0.9943
Rat acute toxicity2.7679 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6238
hERG inhibition (predictor II)Non-inhibitor0.9213
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-6901000000-ccdad7ad5ae99193261b

Taxonomy

Description
This compound belongs to the class of organic compounds known as indazoles. These are compounds containing an indazole, which is structurally characterized by a pyrazole fused to a benzene.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzopyrazoles
Sub Class
Indazoles
Direct Parent
Indazoles
Alternative Parents
Nitroaromatic compounds / Benzenoids / Pyrazoles / Heteroaromatic compounds / Propargyl-type 1,3-dipolar organic compounds / Organic oxoazanium compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic zwitterions
show 2 more
Substituents
Benzopyrazole / Indazole / Nitroaromatic compound / Benzenoid / Azole / Pyrazole / Heteroaromatic compound / C-nitro compound / Organic nitro compound / Organic oxoazanium
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Tetrahydrobiopterin binding
Specific Function
Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induce...
Gene Name
NOS3
Uniprot ID
P29474
Uniprot Name
Nitric oxide synthase, endothelial
Molecular Weight
133287.62 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Tetrahydrobiopterin binding
Specific Function
Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity ...
Gene Name
NOS2
Uniprot ID
P35228
Uniprot Name
Nitric oxide synthase, inducible
Molecular Weight
131116.3 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on June 13, 2005 07:24 / Updated on December 01, 2017 14:54